Erasca, Inc.

NASDAQ:ERAS

Biotechnology

Healthcare
$13.76 -0.14%

-$0.02 today

Market cap
$4.83B
Beta
0.73
P/E (TTM)
-15.3
EPS (TTM)
-$0.91
52W Low $1.21High $24.28

Volume 8.94M

Average 6.79M

ERAS Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Erasca, Inc.NASDAQ: ERAS

Operating Expenses · Q3 FY2026 · quarter ended Sep 2026

Operating expenses growth accelerates

Q3 FY2026 operating expenses of $59.52M rose 72.3% year over year, ahead of the +23.1% change in trailing-twelve-month operating expenses. Sequentially, it rose 25.0% from the prior quarter. Over 3 fiscal years it compounded at -19.4% a year.

Context

  • Operating expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +72.3% holds above the trailing-twelve-month pace of +23.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$59.52M+25.0% QoQ
Last fiscal yearDec 2025
$128.3M-28.6% YoY
LTMSep 2026
$176.19M+23.1% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+72.3%——
1 year-28.6%——
3-year CAGR-19.4%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
128.3M USD
Year-over-year change
-28.6%
4-year CAGR
+0.8%

Operating Expenses vs competitors

How ERAS compares with its peers on the latest reported figures

  • ERAS's LTM Sep 2026 operating expenses of $176.19M is the 6th highest of the 9 companies compared; the peer median is $219.98M.
  • Its year-over-year change of +23.1% is the 6th highest of 9, against a peer median of +29.6%.
  • Over three fiscal years its annual growth of -19.4% compares with a peer median of +37.9%.
ERAS Competitors Peer median
Operating Expenses for ERAS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RVMDRevolution Medicines, Inc.LTM Jun 2026$1.62B +80.3%+58.3%—
KURAKura Oncology, Inc.LTM Mar 2026$385.56M +42.1%+38.4%538.2%
NUVBNuvation Bio Inc.LTM Jun 2026$297.23M +30.0%+30.7%174.9%
TNGXTango Therapeutics, Inc.LTM Sep 2026$227.59M +29.2%+8.0%—
VSTMVerastem, Inc.LTM Mar 2026$212.38M +50.5%+37.4%428.3%
ERASErasca, Inc.LTM Sep 2026$176.19M +23.1%-19.4%—
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$163.78M -44.2%+49.7%72.7%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$156.87M +11.7%+68.8%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$149.59M +2.2%+15.6%—
Peer median (excluding ERAS) $219.98M+29.6%+37.9%301.6%

Competitors are the stored peer set for ERAS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue829K2.64M3.73M03.11M
Gross Profit(829K)(2.64M)(3.73M)0(3.11M)
Gross Margin—————
Research & Development73.92M112.46M103.82M115.36M92.85M
Selling, General & Admin22.62M32.99M37.7M41.73M38.55M
Operating Expenses124.05M244.81M137.79M179.59M128.3M
Depreciation & Amortization829K2.64M3.73M3.81M3.11M
EBITDA(121.94M)(240.16M)(121.31M)(153.28M)(121.44M)
EBITDA Margin—————
Operating Income(124.88M)(247.45M)(141.53M)(179.59M)(131.41M)
Operating Margin—————
Interest Income190K4.9M16.71M20.09M16.61M
Interest Expense0201.36M000
Other Income / Expenses2.12M4.65M16.48M17.94M6.86M
Income Before Tax(122.76M)(242.81M)(125.04M)(161.65M)(124.55M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(122.76M)(242.81M)(125.04M)(161.65M)(124.55M)
Net Margin—————
EPS (Basic)(1.03)(1.99)(0.83)(0.69)(0.44)
EPS (Diluted)(1.03)(1.99)(0.83)(0.69)(0.44)
Weighted Avg Shares119.1M122.02M150.18M233.82M283.53M
Weighted Avg Shares (Diluted)119.1M122.02M150.18M233.82M283.53M

Erasca, Inc.

NASDAQ:ERAS

Intrinsic Alpha fair value

Locked

Current Price

$13.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.